Quantcast
Information About Cancer And Oncology That Everyone Should

Information About Cancer And Oncology That Everyone Should Know

Rayshell Clapper for redOrbit.com - Your Universe Online Cancer is a real concern for many people. The concern may come from a genetic predisposition, environmental triggers, or simply the health-conscious need to have a better understanding of...

Latest immunotherapy Stories

2014-10-31 23:04:18

The Mesothelioma Applied Research Foundation is optimistic about results reported by AduroBioTech, Inc. of their Phase 1b clinical trial of CRs-207, a novel immunotherapy agent. Alexandria, VA (PRWEB) October 31, 2014 The interim results, which were reported during the International Mesothelioma Interest Group’s meeting last week by Raffit Hassan, MD, a researcher at the National Cancer Institute (NCI) and former chair of the Meso Foundation’s Science Advisory Board, were promising....

2014-10-31 08:26:41

Data to be presented in poster presentation beginning Friday November 7; selected for oral presentation Saturday November 8 at 1:40 PM in Exhibit Hall C. ANN ARBOR, Mich., Oct. 31, 2014 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the anti-tumor activity of novel synthetic RORgamma agonist product candidates will be presented at the annual meeting of the...

2014-10-30 12:29:56

HOUSTON, Oct. 30, 2014 /PRNewswire-USNewswire/ -- Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs, and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of The University of Texas MD Anderson Cancer Center's Moon Shots Program. First-of-a-kind combination clinical trials; advanced molecular analysis to guide treatment and screening; and a focused program to gather, store, access...

2014-10-30 04:20:57

AMSTERDAM, October 30, 2014 /PRNewswire/ -- Kiadis Pharma B.V. ("Kiadis Pharma" or "the Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR(TM) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML). Kiadis Pharma has previously been granted an ODD for ATIR(TM) by both the EMA and the FDA for...

2014-10-28 08:36:16

New Personalized Toothpaste Addresses Underlying Cause of Seasonal and Year-Round Allergies MADISON, Wis., Oct. 28, 2014 /PRNewswire/ -- Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent(TM), a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis. Allerdent(TM) is designed for daily use as part of a normal tooth-brushing regimen and enables...

2014-10-27 12:29:54

National patient education organization to host health event during Atlanta Hawks basketball game to give back to the Atlanta community and increase awareness of these life-threatening issues ATLANTA, Oct. 27, 2014 /PRNewswire-USNewswire/ -- Allergy & Asthma Network, the leading national nonprofit patient education organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions, and the American College of Allergy, Asthma and...

2014-10-27 12:29:22

WORCESTER, Mass. and TORONTO, Oct. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced two presentations demonstrating that the extent of the immunological response triggered by its novel proprietary cancer immunotherapeutic AE37 vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc....

2014-10-23 08:36:59

WORCESTER, Mass. and TORONTO, Oct. 23, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 2014 BIO-Europe(®) Annual International Partnering Conference being held November 3-5 in Frankfurt, Germany. BIO-Europe(®) is Europe's largest partnering conference serving the global biotechnology industry. The conference...

2014-10-22 08:31:17

MISSISSAUGA, ON, Oct. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of a market study commissioned to investigate the U.S. opportunity for the Company's experimental immunotherapy product, WF10, as a treatment for patients with refractory allergic rhinitis. The study, performed by Psscion Lifesciences Consulting (Psscion), forecasts that WF10 could capture...

2014-10-15 12:32:29

LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018. This report provides:An overview of the global market for cancer immunotherapiesAnalyses of global market trends, with data from 2012, estimates for 2013, and projections of...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.